Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis.
about
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cellsHER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the StomachBiological markers of invasive breast cancerDiscordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancersUse of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineMaintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review.Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysisCan positron emission tomography/computed tomography with the dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer?--A pilot study.Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors.Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.Organ-specific isogenic metastatic breast cancer cell lines exhibit distinct Raman spectral signatures and metabolomes.Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis.Breast Cancer Biomarkers: Utility in Clinical Practice.Immuno-PET for Clinical Theranostic Approaches.Receptor conversion in metastatic breast cancer: a prognosticator of survivalRelapsed triple-negative breast cancer: challenges and treatment strategies.Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.Pragmatic issues in biomarker evaluation for targeted therapies in cancer.Incorporation of biomarkers in phase II studies of recurrent glioblastoma.Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.Detecting Tumor Metastases: The Road to Therapy Starts Here.Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigationIntrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.Triple-negative breast cancer that progressed as estrogen receptor-positive skin metastases.Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials.Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound-guided transbronchial needle aspiration.Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.Significance of lung biopsy for the definitive diagnosis of lung nodules in breast cancer patients.Prognostic implications of receptor discordance between primary and recurrent breast cancer.Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.Cytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma.Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
P2860
Q26748850-9FDD09C6-0283-48BB-9CDD-7C477B0DDA2CQ26780318-4B729322-F784-40BA-9889-4EB729EE7557Q26781177-AD8D6EBC-BAD4-4395-99E5-FE6A4422F35BQ33699614-D9D5CACF-1EEA-4BD1-8C8F-A2B1CD61812EQ33779282-CAA725FD-0E73-4DDD-9D77-4522CE71BD5FQ33817285-66F051FE-5FEA-42F4-90F7-C85C9D3A9424Q34130140-7EE308C6-A5AA-4D17-B449-168518B6AA2AQ34834419-E0BFC719-A661-4599-8067-4DF978C66AF2Q35036174-61C5738B-897C-43A3-AE73-B446A68C66F7Q35739831-B59EAE50-2CCA-422E-B773-8CDDADAC7E05Q36085375-8A5BE8DE-C3A2-42CE-8243-29AFD9F5F6D9Q36266131-1A1C0F63-6054-4CB6-86D1-8911CE02AEC7Q37316607-A735BA95-6488-4048-950B-CBDC2AA2DC51Q37441159-086A6183-3A02-4D70-B44C-EEE40E6451F0Q37631461-F51C882D-9B63-4770-BF31-333351D07C37Q37687736-472B29CA-C6C0-4F70-B27C-174E5B65F5A4Q38120666-F7399C3C-4006-4B61-8226-950EA0D18D67Q38168792-3CADC0C4-A003-4F72-BF0E-6F00CC69D6A3Q38209464-20C086F9-65DD-448C-9E16-D9C00F9E2A59Q38271031-85A3016A-805B-4E21-85FB-A57D330F9D12Q38298124-5DFA55BA-2E5B-489A-9222-53FF472127ACQ38842674-E008DBCB-38F8-4EF8-A4A0-9EA5F444E937Q38919700-9ADF462D-3C4B-44D4-BB37-9A0B3485C00BQ38950545-1CAE9794-6B4A-4D57-9290-50DE6CD1F779Q39535768-846CE9E6-6F23-40AF-84F6-B0B1E84ACFE0Q41716164-AFD91162-20D9-494D-90BB-1285A9EE7267Q41932946-D78938E8-E239-4EFD-B421-E3952F52CF11Q42506362-FD0C5E2C-AE1B-4405-AE1C-4EB71590EB27Q42544323-0383E293-0D37-40BE-8B42-958481CA3B44Q47994905-8C87E125-D65D-4A9D-9431-3E6F559B8291Q48171311-77CD52F6-B74C-478F-80D1-D26472DABFA4Q48336597-8686B9E2-6CB1-4DF4-9AD8-4284D63EED64Q49796316-042DEAC4-5004-4C76-A70F-66762CAF829CQ50052578-AAA88A58-9AD6-4704-B973-FA5E1ED7D118Q50619195-1F76FEAE-21B6-4BFA-BFF6-2480C8657A66Q51304741-A8E0A656-8878-4E3D-8BA6-9CDB80CC6542Q53277939-979DDBA0-3344-44FF-B855-10CE159604EEQ54322784-98F7AE29-4F7E-44BA-A456-C0B382BE59C2Q55033826-219725EE-7E29-4608-BFB2-8AA7EE270CA8
P2860
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Discordance in receptor status ...... a single-institution analysis.
@en
Discordance in receptor status ...... a single-institution analysis.
@nl
type
label
Discordance in receptor status ...... a single-institution analysis.
@en
Discordance in receptor status ...... a single-institution analysis.
@nl
prefLabel
Discordance in receptor status ...... a single-institution analysis.
@en
Discordance in receptor status ...... a single-institution analysis.
@nl
P2093
P2860
P356
P1433
P1476
Discordance in receptor status ...... a single-institution analysis.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDS248
P577
2012-09-20T00:00:00Z